Gaudium IVF Q1 FY27 Revenue Up 9.1% to ₹19.4 Cr, Focus on Expansion
Gaudium IVF reported Q1 FY27 revenue of ₹19.4 Cr, a 9.1% YoY increase. The company is investing heavily in expansion, planning 27 new hubs. Clinical success rates improved to 62% with AI integration. Gaudium IVF targets 30% revenue growth for FY27 and expects new hubs to break even within 3 months. A new women's hospital in Lucknow is also approved.
The revenue growth is moderate, and while expansion plans are positive, the moderation in EBITDA and PAT due to investments indicates a near-term trade-off. The strategic initiatives like AI integration and new hub openings have a positive long-term impact.
The company reported revenue growth, highlighted improvements in clinical outcomes due to AI integration, and provided a confident outlook for future growth, including expansion plans and achieving revenue targets.
Gaudium IVF and Women Health Limited announced its Q1 FY27 financial results, reporting a revenue growth of 9.1% year-on-year to ₹19.4 crores. The company's EBITDA stood at ₹2.4 crores and PAT at ₹1.8 crores. This moderation in profit is attributed to strategic investments in expansion, including the rollout of 27 new hubs.
The company highlighted its strong clinical performance with a pregnancy success rate of over 58%, which has improved to 62% in the first attempt. Gaudium IVF is also pioneering the use of AI-led embryology tools, SiD and ERICA, which have shown an approximate 8% improvement in first-attempt outcomes. This technology integration makes Gaudium IVF the first in India to adopt such advanced embryology practices.
Strategically, the company operationalized its first new hub at South Extension, New Delhi, on July 16, 2026, as part of its IPO-funded expansion plan. Further expansion includes new hubs in Gurgaon and Nagpur, with timelines of 10 and 25 days respectively. The company is on track to achieve its target of 10 new hubs in FY27, followed by eight in FY28 and one in FY29. Additionally, three international spokes are progressing in Paris, Nigeria, and Sydney. Gaudium IVF also received board approval for a Gaudium Women Hospital in Lucknow, to be funded through internal accruals, with commercialization expected in FY28-FY29.
The company reaffirmed its confidence in achieving its stated FY27 revenue targets, projecting a 30% growth for the full fiscal year, with adjusted EBITDA margins expected to return to FY26 levels by year-end. New hubs are expected to break even within three months of operation. The average revenue per patient, excluding certain services, is approximately ₹4 lakhs, with an average construction cost per hub of ₹2.5 crores.
What to do with a filing like this
Gaudium IVF and Women Health Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gaudium IVF and Women Health Limited. Read the original for the full detail.